Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2022

01-05-2022 | Carbapenem Antibiotic | Brief Report

Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting

Authors: Burcu Isler, Berna Özer, Güle Çınar, Abdullah Tarık Aslan, Cansel Vatansever, Caitlin Falconer, İştar Dolapçı, Funda Şimşek, Necla Tülek, Hamiyet Demirkaya, Şirin Menekşe, Halis Akalin, İlker İnanç Balkan, Mehtap Aydın, Elif Tükenmez Tigen, Safiye Koçulu Demir, Mahir Kapmaz, Şiran Keske, Özlem Doğan, Çiğdem Arabacı, Serap Yağcı, Gülşen Hazırolan, Veli Oğuzalp Bakır, Mehmet Gönen, Mark D. Chatfield, Brian Forde, Neşe Saltoğlu, Alpay Azap, Özlem Azap, Murat Akova, David L. Paterson, Füsun Can, Önder Ergönül

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2022

Login to get access

Abstract

A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.
Literature
1.
Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19:56–66CrossRef
2.
Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF (2020) Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013–17. J Antimicrob Chemother 75:1165–1173CrossRef
3.
David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G, Aspbury M, Sjunnebo S, Feil EJ, Rossolini GM, Aanensen DM, Grundmann H (2019) Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 4:1919–1929CrossRef
4.
Avolio M, Vignaroli C, Crapis M, Camporese A (2017) Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016. Future Microbiol 12:1119–1122CrossRef
5.
6.
Jeong SH, Lee KM, Lee J, Bae IK, Kim JS, Kim HS, Song W (2015) Clonal and horizontal spread of the blaOXA-232 gene among Enterobacteriaceae in a Korean hospital. Diagn Microbiol Infect Dis 82:70–72CrossRef
7.
Potron A, Rondinaud E, Poirel L, Belmonte O, Boyer S, Camiade S, Nordmann P (2013) Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae. Int J Antimicrob Agents 41:325–329CrossRef
8.
Oueslati S, Nordmann P, Poirel L (2015) Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J Antimicrob Chemother 70:1059–1063CrossRef
9.
Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, Venditti M, Tumbarello M, Daikos G, Canton R, Doi Y, Tuon FF, Karaiskos I, Perez-Nadales E, Schwaber MJ, Azap OK, Souli M, Roilides E, Pournaras S, Akova M, Perez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodriguez-Bano J (2017) Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 17:726–734CrossRef
10.
11.
Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH, McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W (2019) Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrob Agents Chemother 63(11):e00483–19. https://​doi.​org/​10.​1128/​AAC.​00483-19
12.
Pitout JDD, Peirano G, Kock MM, Strydom K-A, Matsumura Y (2019) The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 33:e00102-e119CrossRef
13.
Shankar C, Venkatesan M, Rajan R, Mani D, Lal B, Prakash JAJ, Anandan S, Pragasam AK, Walia K, Ohri VC, Veeraraghavan B (2019) Molecular characterization of colistin-resistant Klebsiella pneumoniae & its clonal relationship among Indian isolates. Indian J Med Res 149:199–207CrossRef
14.
Wyres KL, Nguyen TNT, Lam MMC, Judd LM, van Vinh CN, Dance DAB, Ip M, Karkey A, Ling CL, Miliya T, Newton PN, Lan NPH, Sengduangphachanh A, Turner P, Veeraraghavan B, Vinh PV, Vongsouvath M, Thomson NR, Baker S, Holt KE (2020) Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella pneumoniae from South and Southeast Asia. Genome Med 12:11CrossRef
15.
Shankar C, Mathur P, Venkatesan M, Pragasam AK, Anandan S, Khurana S, Veeraraghavan B (2019) Rapidly disseminating blaOXA-232 carrying Klebsiella pneumoniae belonging to ST231 in India: multiple and varied mobile genetic elements. BMC Microbiol 19:137CrossRef
16.
17.
Ludden C, Lötsch F, Alm E, Kumar N, Johansson K, Albiger B, Huang TD, Denis O, Hammerum AM, Hasman H, Jalava J, Räisänen K, Dortet L, Jousset AB, Gatermann S, Haller S, Cormican M, Brennan W, Del Grosso M, Monaco M, Schouls L, Samuelsen Ø, Pirš M, Cerar T, Oteo-Iglesias J, Pérez-Vázquez M, Sjöström K, Edquist P, Hopkins KL, Struelens MJ, Palm D, Monnet DL, Kohlenberg A (2020) Cross-border spread of bla (NDM-1)- and bla (OXA-48)-positive Klebsiella pneumoniae: a European collaborative analysis of whole genome sequencing and epidemiological data, 2014 to 2019. Euro Surveill 25
18.
Moubareck CA, Mouftah SF, Pal T, Ghazawi A, Halat DH, Nabi A, AlSharhan MA, AlDeesi ZO, Peters CC, Celiloglu H, Sannegowda M, Sarkis DK, Sonnevend A (2018) Clonal emergence of Klebsiella pneumoniae ST14 co-producing OXA-48-type and NDM carbapenemases with high rate of colistin resistance in Dubai, United Arab Emirates. Int J Antimicrob Agents 52:90–95CrossRef
19.
20.
21.
Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A (2011) Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798–1803CrossRef
22.
Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL (2014) Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862–872CrossRef
Metadata
Title
Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting
Authors
Burcu Isler
Berna Özer
Güle Çınar
Abdullah Tarık Aslan
Cansel Vatansever
Caitlin Falconer
İştar Dolapçı
Funda Şimşek
Necla Tülek
Hamiyet Demirkaya
Şirin Menekşe
Halis Akalin
İlker İnanç Balkan
Mehtap Aydın
Elif Tükenmez Tigen
Safiye Koçulu Demir
Mahir Kapmaz
Şiran Keske
Özlem Doğan
Çiğdem Arabacı
Serap Yağcı
Gülşen Hazırolan
Veli Oğuzalp Bakır
Mehmet Gönen
Mark D. Chatfield
Brian Forde
Neşe Saltoğlu
Alpay Azap
Özlem Azap
Murat Akova
David L. Paterson
Füsun Can
Önder Ergönül
Publication date
01-05-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2022
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-022-04425-4

Other articles of this Issue 5/2022

European Journal of Clinical Microbiology & Infectious Diseases 5/2022 Go to the issue

Original Article

Clinical and microbiological characterization of Aerococcus urinae bacteraemias at Helsinki metropolitan area, Finland

Original Article

Validation of Rapid Antimicrobial Susceptibility Testing directly from blood cultures using WASPLab®, including Colibrí™ and Radian® in-Line Carousel

Original Article

Risk factors for antibiotic resistance and mortality in patients with bloodstream infection of Escherichia coli

Original Article

A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections

Brief Report

Transition to PCR diagnosis of cryptosporidiosis and giardiasis in the Norwegian healthcare system: could the increase in reported cases be due to higher sensitivity or a change in the testing algorithm?

Original Article

Non-structural protein 1 (NS1) variants from dengue virus clinical samples revealed mutations that influence NS1 production and secretion
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits